Literature DB >> 27995437

Toward Personalized Targeted Therapeutics: An Overview.

Shiao-Pei S Weathers1, Mark R Gilbert2.   

Abstract

In neuro-oncology, there has been a movement towards personalized medicine, or tailoring treatment to the individual patient. Ideally, tumor and patient evaluations would lead to the selection of the best treatment (based on tumor characterization) and the right dosing schedule (based on patient characterization). The recent advances in the molecular analysis of glioblastoma have created optimism that personalized targeted therapy is within reach. Although our understanding of the molecular complexity of glioblastoma has increased over the years, the path to developing effective targeted therapeutic strategies is wrought with many challenges, as described in this review. These challenges include disease heterogeneity, clinical and genomic patient variability, limited number of effective treatments, clinical trial inefficiency, drug delivery, and clinical trial support and accrual. To confront these challenges, it will be imperative to devise innovative and adaptive clinical trials in order to accelerate our efforts in improving the outcomes for our patients who have been in desperate need.

Entities:  

Keywords:  Glioblastoma; Glioma; Personalized medicine; Targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 27995437      PMCID: PMC5398979          DOI: 10.1007/s13311-016-0496-5

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  45 in total

1.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

Authors:  E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

Review 2.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Authors:  William Pao; Juliann Chmielecki
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

3.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Authors:  B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

4.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

5.  Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.

Authors:  Terri S Armstrong; Yumei Cao; Michael E Scheurer; Elizabeth Vera-Bolaños; Rochelle Manning; Mehmet F Okcu; Melissa Bondy; Renke Zhou; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

6.  Tumour heterogeneity in the clinic.

Authors:  Philippe L Bedard; Aaron R Hansen; Mark J Ratain; Lillian L Siu
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

Review 7.  Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.

Authors:  Alba A Brandes; Enrico Franceschi; Alicia Tosoni; Monika E Hegi; Roger Stupp
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

8.  A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

Authors:  Edgar R Wood; Anne T Truesdale; Octerloney B McDonald; Derek Yuan; Anne Hassell; Scott H Dickerson; Byron Ellis; Christopher Pennisi; Earnest Horne; Karen Lackey; Krystal J Alligood; David W Rusnak; Tona M Gilmer; Lisa Shewchuk
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

9.  The BATTLE trial: personalizing therapy for lung cancer.

Authors:  Edward S Kim; Roy S Herbst; Ignacio I Wistuba; J Jack Lee; George R Blumenschein; Anne Tsao; David J Stewart; Marshall E Hicks; Jeremy Erasmus; Sanjay Gupta; Christine M Alden; Suyu Liu; Ximing Tang; Fadlo R Khuri; Hai T Tran; Bruce E Johnson; John V Heymach; Li Mao; Frank Fossella; Merrill S Kies; Vassiliki Papadimitrakopoulou; Suzanne E Davis; Scott M Lippman; Waun K Hong
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

10.  Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting.

Authors:  Chien-Yu Lu; Ching-Wen Huang; I-Chen Wu; Hsiang-Lin Tsai; Cheng-Jen Ma; Yung-Sung Yeh; Se-Fen Chang; Meng-Lin Huang; Jaw-Yuan Wang
Journal:  Transl Oncol       Date:  2015-12       Impact factor: 4.243

View more
  10 in total

1.  Magnetic calcium phosphates nanocomposites for the intracellular hyperthermia of cancers of bone and brain.

Authors:  Alessio Adamiano; Victoria M Wu; Francesca Carella; Gianrico Lamura; Fabio Canepa; Anna Tampieri; Michele Iafisco; Vuk Uskoković
Journal:  Nanomedicine (Lond)       Date:  2019-05       Impact factor: 5.307

2.  Glioma targeting peptide in combination with the P53 C terminus inhibits glioma cell proliferation in vitro.

Authors:  Dan Wang; Meihua Guo; Jiawen Yu; Xinying Wang; Qian Zhang; Xu Yang; Jiaqi Li; Chunhui Zhao; Bin Feng
Journal:  Cytotechnology       Date:  2017-09-06       Impact factor: 2.058

Review 3.  Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma.

Authors:  Matthew A Taylor; Bhaskar C Das; Swapan K Ray
Journal:  Apoptosis       Date:  2018-12       Impact factor: 4.677

Review 4.  Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.

Authors:  S Lheureux; C Denoyelle; P S Ohashi; J S De Bono; F M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-10       Impact factor: 9.236

Review 5.  New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection.

Authors:  Jan Korbecki; Izabela Gutowska; Ireneusz Kojder; Dariusz Jeżewski; Marta Goschorska; Agnieszka Łukomska; Anna Lubkowska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Oncotarget       Date:  2018-01-09

Review 6.  Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery.

Authors:  Rebekah Omarkhail Elliott; Mei He
Journal:  Pharmaceutics       Date:  2021-01-19       Impact factor: 6.321

Review 7.  Overcoming key biological barriers to cancer drug delivery and efficacy.

Authors:  Susy M Kim; Peggy H Faix; Jan E Schnitzer
Journal:  J Control Release       Date:  2017-09-14       Impact factor: 9.776

Review 8.  MRI and PET of Brain Tumor Neuroinflammation in the Era of Immunotherapy, From the AJR Special Series on Inflammation.

Authors:  Cymon N Kersch; Prakash Ambady; Bronwyn E Hamilton; Ramon F Barajas
Journal:  AJR Am J Roentgenol       Date:  2021-07-14       Impact factor: 6.582

9.  Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.

Authors:  Elisabeth M P Steeghs; Leonie I Kroeze; Bastiaan B J Tops; Leon C van Kempen; Arja Ter Elst; Annemiek W M Kastner-van Raaij; Sandra J B Hendriks-Cornelissen; Mandy J W Hermsen; Erik A M Jansen; Petra M Nederlof; Ed Schuuring; Marjolijn J L Ligtenberg; Astrid Eijkelenboom
Journal:  BMC Cancer       Date:  2020-04-07       Impact factor: 4.430

Review 10.  MYC in Brain Development and Cancer.

Authors:  Olga Zaytseva; Nan-Hee Kim; Leonie M Quinn
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.